Entrega de las becas de investigación de la Asociación de IC a los mejores proyectos en el congreso #SEC2025

12➕1 actualizaciones en la patología #CardioRenal 📢No te pierdas la nueva 💊 de octubre! 🆕Obesidad: abordaje en el paciente CRM https://t.co/d1CIdwk8V5 De la mano del gran @ZorbaBlazquez @Sociedad_SEMI @SENefrologia @ICardiacaSEC @secardiologia

🚨Doctors in Spain are striking. Why? Because our working conditions are unsustainable 🔹 Our base salary is ~€1,300/month. The rest comes from on-calls or “continuity shifts”, meaning we only earn a decent wage by working excessive hours often exceeding 60-70h/week 🔹on-calls

✨ Ya disponible en #CanalSEC la Reunión Anual de la Asociación de #InsuficienciaCardiaca 25: https://t.co/omiXiDJHpL Un programa único sobre IC con FEVI preservada, cuádruple terapia, manejo diurético, hipertensión pulmonar y mucho más. 🔑 Socios SEC: acceso directo con

🔓 Inscripciones abiertas para formar parte de una nueva edición del Curso de #Cardionefrología dirigido a R2 nefrología, socios S.E.N. #CareSen 👉 Madrid, 27-29 noviembre 👌Apúntate hasta el 4 de septiembre Dirigen @Dr_Bqg y @mmvidas INFO: https://t.co/XRA9XKJZjC

12➕1 actualizaciones en la patología #CardioRenal 📢No te pierdas la nueva 💊 de septiembre! 🆕Dislipidemia: objetivos terapéuticos en pacientes cardiorenometabólicos https://t.co/DBorNnKzef Con el gran @yulnunezvill @Sociedad_SEMI @SENefrologia @ICardiacaSEC @secardiologia

Prospective study: #ddcfDNA showed superior performance in predicting rejection by MMDx (AUC 0.89) with an optimal cut-off value of 0.26% than by histology (AUC 0.64). Helps clinicians refine testing & management for patients with elevated dd-cfDNA 🔗:

https://t.co/PLqAk0e6sL

Has the time come to discontinue anticoagulation after an effective AF ablation? #ESCCongress

ENVAD-HF: sacubitril/valsartan in Heartmate 3 LVAD recipients #ESCCongress

Lifetime Benefits of Combination Therapy in HFpEF by @mvaduganathan in #ESCCongress

#ESCCongress Changing landscape and evolving opportunities in heart failure: lessons from Colombia and Spain

Presented at #ESCCongress: In patients with STEMI with cardiogenic shock, early mechanical support with a microaxial pump reduced the risk of death at 180 days, with the survival benefit persisting up to 10 years despite device-related complications. Full DanGer Shock trial

#ESC2025 #SimPub: CASTLE-HTx 3-year outcomes: In patients with end-stage heart failure, AF ablation sustained survival & reduced the need for surgical HF therapies over 36 months, with fewer deaths & LVAD/HTx procedures than medical therapy alone. https://t.co/9bEJmD5EN5

Simultaneous publication during #ESCCongress Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure - https://t.co/OTrcqerfmF #EHJ

Original Article: Multidomain Rehabilitation for Older Patients with Myocardial Infarction (PIpELINe trial) https://t.co/zHTQr6wv9y #ESCCongress | @escardio

Presented at #ESCCongress: In patients with provoked venous thromboembolism and ongoing risk factors, extended treatment with low-dose apixaban for 12 months resulted in a lower risk of recurrent VTE than placebo, with a low risk of major bleeding. Full HI-PRO trial results:

Original Article: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias (POTCAST trial) https://t.co/6HUcV2CkKq #ESCCongress | @escardio

Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8mpwOpVo7U #ESCCongress | @escardio

https://t.co/xt5jdM0Txf